Sandoz signs cancer drug deal with EirGenix

19:00 EDT 30 Apr 2019 | Pharmaceutical Technology

Sandoz has signed an agreement with EirGenix for the commercialisation of a trastuzumab biosimilar. Trastuzumab is a monoclonal antibody (mAb) designed to...

The post Sandoz signs cancer drug deal with EirGenix appeared first on Pharmaceutical Technology.

Original Article: Sandoz signs cancer drug deal with EirGenix


More From BioPortfolio on "Sandoz signs cancer drug deal with EirGenix"

Quick Search

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...